Optimer Pharmaceuticals (OPTR) Tops Q4 EPS Views; Revs Heavy
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Financial Fact:
Research and development: 10.94M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Financial Fact:
Research and development: 10.94M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Optimer Pharmaceuticals (NASDAQ: OPTR) reported Q4 EPS of $0.28, $0.17 better than the analyst estimate of $0.11. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $43.19 million.
For earnings history and earnings-related data on Optimer Pharmaceuticals (OPTR) click here.
For earnings history and earnings-related data on Optimer Pharmaceuticals (OPTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
- Science Applications (SAIC) PT Raised to $154 at Stifel
- RBC Capital Downgrades GQG Partners Inc (GQG:AU) to Sector Perform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
